Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapeutics that modulate endocannabinoid signaling pathways. The company operates within the biotechnology and pharmaceutical industries, with an emphasis on addressing medical conditions that involve metabolic, neurological, and inflammatory processes. Artelo’s strategy centers on identifying well-defined biological targets within the endocannabinoid system and advancing small-molecule drug candidates through clinical development.
The company’s primary revenue driver is currently research and development activity, as it does not generate commercial product revenue. Artelo primarily serves patients with unmet medical needs in areas such as cancer-related anorexia, cachexia, and certain neurological or psychiatric conditions. Its positioning is differentiated by a focus on non-plant-derived cannabinoid pathway modulation, aiming to avoid regulatory and safety challenges associated with botanical cannabinoids. Artelo was originally founded in 2011 and later rebranded as Artelo Biosciences following a strategic shift toward cannabinoid science; it became publicly traded through a reverse merger and now trades on the Nasdaq Capital Market under the ticker ARTL.
Business Operations
Artelo’s operations are organized around a single operating segment: pharmaceutical research and development, encompassing discovery, preclinical research, and early-stage clinical trials. The company’s development pipeline includes proprietary drug candidates designed to selectively target components of the endocannabinoid system, including fatty acid binding proteins and cannabinoid-related signaling mechanisms. Its lead development programs are internally developed and supported by preclinical and early clinical data, though no products have yet reached commercialization.
The company conducts operations primarily through its wholly owned subsidiary, Artelo Biosciences USA, Inc., and relies on a combination of internal scientific leadership and contract research organizations for laboratory work and clinical trial execution. Artelo does not currently report material revenue from partnerships or licensing arrangements, and its activities are funded mainly through equity offerings and other capital-raising transactions. Data regarding specific commercialization partnerships or late-stage development collaborations remains inconclusive based on available public sources.
Strategic Position & Investments
Artelo’s strategic direction is focused on advancing its clinical pipeline, particularly its lead candidate ART27.13, which is being studied for the treatment of cancer-related anorexia and cachexia. The company is also developing earlier-stage assets targeting neuropsychiatric and inflammatory indications, including programs designed to deliver more precise modulation of cannabinoid-related pathways without psychoactive effects. These initiatives reflect a broader industry trend toward mechanism-driven cannabinoid science rather than plant-based formulations.
The company has historically grown through asset acquisitions and in-licensing transactions, acquiring intellectual property that aligns with its cannabinoid signaling strategy. Artelo’s investment priorities emphasize capital efficiency, orphan or high-unmet-need indications, and the potential for regulatory pathways such as Fast Track or Orphan Drug designation. Information regarding material equity investments in external portfolio companies is inconclusive based on available public disclosures.
Geographic Footprint
Artelo Biosciences is headquartered in San Diego, California, within the United States, and its executive management and strategic decision-making are primarily based there. The company’s research and development activities are largely U.S.-centric, though it engages internationally through global clinical trial sites, academic collaborators, and contract research organizations as needed to support development programs.
While Artelo does not maintain a broad physical presence across multiple continents, its intellectual property portfolio and clinical development strategy have international relevance, particularly in North America and Europe, where regulatory frameworks support cannabinoid-related pharmaceutical research. The company does not currently report material foreign manufacturing or commercial operations.
Leadership & Governance
Artelo is led by an experienced management team with backgrounds in pharmaceutical development, corporate finance, and cannabinoid science. The leadership emphasizes capital discipline, scientific rigor, and targeted clinical development aimed at maximizing shareholder value while addressing unmet medical needs. Governance is overseen by a board of directors with experience in biotechnology and public company management.
Key executives include:
- Andrew G. Yates, Ph.D. – President & Chief Executive Officer
- Jonathon Asher – Chief Financial Officer
- Andrew D. Friedman, Ph.D. – Chief Scientific Officer
Information regarding additional executive officers or recent leadership changes beyond these roles is inconclusive based on available public sources.